Abstract
In this review, we explore the biology of the TIGIT checkpoint and its potential as a therapeutic target in lung cancer. We briefly review a highly selected set of clinical trials that have reported or are currently recruiting in non-small cell and small cell lung cancer, a disease transformed by the advent of PD-1/PD-L1 checkpoint blockade immunotherapy. We explore the murine data underlying TIGIT blockade and further explore the reliance of effective anti-TIGIT therapy on DNAM-1(CD226)-positive activated effector CD8+ T cells. The synergism with anti-PD-1 therapy is also explored. Future directions in the realm of overcoming resistance to checkpoint blockade and extending the repertoire of other checkpoints are also briefly explored.
Original language | English |
---|---|
Article number | ltad009 |
Pages (from-to) | 1-6 |
Number of pages | 6 |
Journal | Immunotherapy Advances |
Volume | 3 |
Issue number | 1 |
DOIs | |
Publication status | Published - 26 May 2023 |
Bibliographical note
© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Immunology.Keywords
- TIGIT
- lung cancer
- non-small cell lung cancer
- small cell lung cancer
- immunotherapy